Immunometabolic editing of the tumor microenvironment: from reprogramming mechanisms to therapeutic vulnerabilities
Top Cited Papers
Open Access
- 16 January 2026
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 16, 1678446
Abstract
Metabolic reprogramming is not only one of the malignant characteristics of tumor cells, but also commonly seen in a variety of immune cells in tumor microenvironment(TME), which massively promotes tumor-body immune interaction. Immunometabolic editing is a dynamic, co-evolutionary process wherein adaptive metabolic reprogramming in the TME, driven by tumor-immune crosstalk during immunoediting, critically shapes anti-tumor immune response and governs immune evasion. Studies of metabolic pathways linked to anti-tumor immune process and discoveries of important therapeutic targets are conducive to the development of targeted immunometabolic intervention to enhance the body’s anti-tumor immune response and improve the efficacy of tumor immunotherapies. This review summarizes metabolic characteristics of the TME, highlights immunometabolic editing during cancer evolution, and discusses mechanisms by which tumor immunotherapies modulate tumor immunometabolism to identify potential therapeutic targets.Keywords
This publication has 100 references indexed in Scilit:
- Metabolomic profiling of childhood medulloblastoma: contributions and relevance to diagnosis and molecular subtypingJournal of Cancer Research and Clinical Oncology, 2024
- New insights into immune cells in cancer immunotherapy: from epigenetic modification, metabolic modulation to cell communicationMedcomm, 2024
- The inhibitory effect of adenosine on tumor adaptive immunity and intervention strategiesActa Pharmaceutica Sinica B, 2023
- Metabolic reprogramming, autophagy, and ferroptosis: Novel arsenals to overcome immunotherapy resistance in gastrointestinal cancerCancer Medicine, 2023
- The Warburg effect: a score for many instruments in the concert of cancer and cancer niche cellsPharmacological Reports, 2023
- Immune cell metabolism and metabolic reprogrammingMolecular Biology Reports, 2022
- Potentiating CD8+ T cell antitumor activity by inhibiting PCSK9 to promote LDLR-mediated TCR recycling and signalingProtein & Cell, 2021
- The EGFR‐P38 MAPK axis up‐regulates PD‐L1 through miR‐675‐5p and down‐regulates HLA‐ABC via hexokinase‐2 in hepatocellular carcinoma cellsCancer Communications, 2021
- Current trends in drug metabolism and pharmacokineticsActa Pharmaceutica Sinica B, 2019
- L-Norvaline Reverses Cognitive Decline and Synaptic Loss in a Murine Model of Alzheimer's DiseaseNeurotherapeutics, 2018